Richard J. Lewis
Corporate Officer/Principal chez The University of Queensland
Profil
Richard J.
Lewis was the founder of Xenome Ltd.
which was founded in 2000, where he held the title of Chief Scientific Officer from 2000 to 2011.
Currently, he holds the title of Principal at The University of Queensland and National Health & Medical Research Council.
In the past, he held the title of Principal at Molecular Pharmacology (USA) Ltd.
Postes actifs de Richard J. Lewis
| Sociétés | Poste | Début |
|---|---|---|
| The University of Queensland | Corporate Officer/Principal | 01/07/2009 |
| National Health & Medical Research Council | Corporate Officer/Principal | 01/07/2009 |
Anciens postes connus de Richard J. Lewis
| Sociétés | Poste | Fin |
|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Corporate Officer/Principal | - |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Entreprise privées | 2 |
|---|---|
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
| National Health & Medical Research Council | Government |
